Target $65 implies 27% upside vs $51.05 but DCF FV=$16 is clearly broken/stale. Bio-Techne is high-quality life sciences tools with strong recurring revenue mix. Life sciences tools sector broadly under pressure from biopharma budget cuts. Thesis intact long-term but need fresh DCF to justify above neutral.
Fair Value Distribution — percentile bands
0.0% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
32.1%/yr
±4.4% · revenue growth to justify current price
FCF-Based Reverse DCF
29.1%/yr
±3.2% · FCF growth to justify current price
THE GAP
Market pricing margin expansion or capex normalization
KEY VALUE DRIVERS
Spearman correlation — what moves this valuation most
Eagle will generate this view by the next trading session (~7h).
Eagle will generate this view by the next trading session (~7h).
TECH flat organic growth stalled at flat. Margin compression from unfavorable product mix. Exosome divestiture successful at improving Diagnostics segment (10.4% margin post-divestiture vs 3.9% pre). ...